Abstracts tagged "Idiopathic Inflammatory Myopathies (IIM)"

Abstract Number: 2063 • 2013 ACR/ARHP Annual Meeting
Identification Of Autoantibodies To Tyrosyl–Transfer RNA Synthetase Associated With Anti-Synthetase Syndrome
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Koji Tahara², Kaori Ito², Hiroaki Hattori², Takahisa Gono¹, Kae Takagi¹, Masanori Hanaoka¹, Yuko Ota¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Advanced Medical Technology and Development, BML, Saitama, Japan
Background/Purpose : Autoantibodies directed against the aminoacyl transfer RNA (tRNA) synthetases are associated with myositis, arthritis, Raynaud’s phenomenon, mechanic’s hands, fever, and interstitial lung disease,…
Abstract Number: 2065 • 2013 ACR/ARHP Annual Meeting
The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies
Xin Lu¹, Guochun Wang², Qinglin Peng³, Kai Yuan⁴ and Hanbo Yang⁵, ¹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, Beijing, China, ²Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ³Department of Rheumatology,, China-Japan Friendship Hospital, Beijing, China, ⁴Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ⁵Rheumatology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: To determine the sera levels of anti-NXP-2 antibodies and their clinical association in Chinese patients with idiopathic inflammatory myopathies(IIM). Methods: Sera from 198 Chinese…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].